ICYMI: 🟢 $WVE +146% (Wave Life Sciences shared interim data from the lowest therapeutic cohort of the ongoing first-in-human INLIGHT trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design, for obesity.) 🟢 $GPCR +102% (Structure https://t.co/SPGbMQLqL1






